Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma

[1]  G. Kaushal,et al.  Epigenetic regulation of KLK7 gene expression in pancreatic and cervical cancer cells , 2016, Biological chemistry.

[2]  Holly S Stevenson,et al.  Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma , 2015, Modern Pathology.

[3]  M. Okada,et al.  Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer , 2015, Cancer medicine.

[4]  Satoru Miyano,et al.  Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma , 2015, Nature Communications.

[5]  M. Ringnér,et al.  Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. , 2015, The Journal of investigative dermatology.

[6]  Young-Joon Kim,et al.  The regulatory mechanisms of intragenic DNA methylation. , 2015, Epigenomics.

[7]  C. Weng,et al.  Global methylation silencing of clustered proto-cadherin genes in cervical cancer: serving as diagnostic markers comparable to HPV , 2014, Cancer medicine.

[8]  Jun Yu,et al.  Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer. , 2014, Journal of the American College of Surgeons.

[9]  Ying-li Lin,et al.  Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer , 2014, The Journal of international medical research.

[10]  M. Esteller,et al.  Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth , 2014, Oncotarget.

[11]  Byung Jin Byun,et al.  Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[12]  R. Kappler,et al.  Identification of BMP2 as an epigenetically silenced growth inhibitor in rhabdomyosarcoma. , 2014, International journal of oncology.

[13]  C. Cinti,et al.  Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line , 2014, PloS one.

[14]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[15]  F. Barr,et al.  Classification of Rhabdomyosarcoma and Its Molecular Basis , 2013, Advances in Anatomic Pathology.

[16]  S. Spunt,et al.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas , 2013, Pediatric blood & cancer.

[17]  Jing Shen,et al.  Genome‐wide DNA methylation profiles in hepatocellular carcinoma , 2012, Hepatology.

[18]  Zizhen Yao,et al.  Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas , 2012, Epigenetics.

[19]  G. Hampton,et al.  DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[20]  K. Yamagata,et al.  Non-clustered protocadherin , 2011, Cell adhesion & migration.

[21]  Faming Liang,et al.  A hidden Ising model for ChIP-chip data analysis , 2010, Bioinform..

[22]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Orr-Urtreger,et al.  FGFR1 over‐expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5′ CpG Island and abnormal expression of the AKT1, NOG, and BMP4 genes , 2007, Genes, chromosomes & cancer.

[24]  A. Iolascon,et al.  Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation. , 2006, Carcinogenesis.

[25]  T. Triche,et al.  Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. , 2006, Cancer research.

[26]  Cesare Furlanello,et al.  Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3‐FKHR positive and negative tumors , 2006, International journal of cancer.

[27]  D. Parham,et al.  Upstream CpG island methylation of the PAX3 gene in human rhabdomyosarcomas , 2005, Pediatric blood & cancer.

[28]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[29]  Kenichi Harada,et al.  Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines , 2002, Oncogene.

[30]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[31]  R. Momparler,et al.  Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. , 2001, Lung cancer.

[32]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[33]  T. Maniatis,et al.  A Striking Organization of a Large Family of Human Neural Cadherin-like Cell Adhesion Genes , 1999, Cell.

[34]  T. Triche,et al.  Myc Oncogene Expression and Nude Mouse Tumorigenicity and Metastasis Formation Are Higher in Alveolar than Embryonal Rhabdomyosarcoma Cell Lines , 1999, Pediatric Research.

[35]  D. Parham,et al.  Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas. , 1998, The American journal of pathology.

[36]  J. Downing,et al.  Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. , 1993, Cancer research.

[37]  C. Plass,et al.  Genome-wide epigenetic modifications in cancer. , 2011, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[38]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[39]  James R. Anderson,et al.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.